The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

WW International (NASDAQ:WW), more commonly known as WeightWatchers, will now offer compounded semaglutide to its WeightWatchers Clinic members, expanding the accessibility of popular weight loss medications to its members at a more affordable price.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.

WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.